With all the buzz in gene therapy, Sanofi offloads two small molecule sickle cell programs from $11.6B buyout to Global Blood Therapeutics
Standing by a small molecule approach in sickle cell disease even as gene therapy and gene editing players tout landmark breakthroughs, Global Blood Therapeutics has turned to Sanofi to beef up its pipeline.
GBT, which already has one approved sickle cell drug in Oxbryta, is plucking two early-stage discovery programs from a lower profile branch of the Bioverativ business that Sanofi acquired for $11.6 billion in 2018: one pursuing a new anti-sickling mechanism and the other aiming to reduce inflammation and oxidative stress.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.